A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

Pharmaceutical share prices fell last Monday, after US President Donald Trump vowed to reduce drug prices in the USA by as ...

Novo Nordisk announced it will work with the biotech Septerna to develop oral GLP-1 obesity drugs in a deal worth up to $2.2 ...

Currently, the analyst consensus on GlaxoSmithKline is a Hold with an average price target of p1,404.46, implying a 3.27% upside from current levels. In a report released yesterday, Goldman Sachs also ...

Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a ...

GSK plc with its development partner iTeos Therapeutics, Inc., has announced that it is ending the development programme for ...